Resverlogix Corp
Company Profile
Business description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Contact
4820 Richard Road SW
Suite 300
CalgaryABT3E 6L1
CANT: +1 403 254-9252
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
stocks
Investors overlooking ASX share’s potential
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,735.40 | 83.10 | -0.94% |
| CAC 40 | 7,981.61 | 29.06 | 0.37% |
| DAX 40 | 24,336.31 | 385.74 | 1.61% |
| Dow JONES (US) | 49,506.39 | 19.78 | -0.04% |
| FTSE 100 | 10,289.21 | 93.84 | 0.92% |
| HKSE | 25,675.18 | 287.55 | -1.11% |
| NASDAQ | 26,225.14 | 410.08 | -1.54% |
| Nikkei 225 | 60,815.95 | 593.34 | -0.97% |
| NZX 50 Index | 12,762.92 | 202.09 | -1.56% |
| S&P 500 | 7,418.39 | 9.89 | 0.13% |
| S&P/ASX 200 | 8,505.30 | 72.60 | -0.85% |
| SSE Composite Index | 4,131.53 | 3.86 | -0.09% |